RESEARCH
Our commitment to longevity research
As a community of longevity experts, doctors, and scholars, AgelessRx is fully committed to the invaluable role research plays in medicine and the limitless opportunities it presents for the future. In that spirit, AgelessRx is proud to play a leading role in discovering new, scientifically proven treatment options that prevent age-related diseases and reverse age-related damage.
Rapamycin Trial
Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL)
Rapamycin is an FDA-approved antifungal agent, most used to prevent organ transplant rejection. Rapamycin targets the mTOR signaling pathway, which is associated with many aging-related diseases.
PEARL is a double-blind, randomized, placebo-controlled trial. Notably, it is the first nationwide telemedicine trial and the first large-scale intervention trial on longevity. PEARL is proudly sponsored by AgelessRx and affiliated with the University of California.
Learn more
LDN Registry
The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging
Are you currently taking LDN? If yes, participate in our LDN Registry to help us collect valuable information on the benefits you’re experiencing! This trial aims to provide prescribers and the entire longevity community with better-informed usage insight on LDN as a longevity therapy.
Learn morePost-COVID-19 Trial
Pilot Study into Low Dose Naltrexone (LDN) and NAD+ for Treatment of Patients with Post-COVID-19 Syndrome
Proudly sponsored by AgelessRx, this double-blind placebo-controlled pilot study will assess the use of Low Dose Naltrexone (LDN) and NAD+ for the treatment of patients with post-COVID-19 syndrome (long-COVID-19).
AgelessRx will enroll over 60 people (must have had a positive test for SARS-CoV-2 1-4 months before enrollment) for a 12-week study. Patients will receive LDN and NAD+ treatment or a corresponding placebo tablet and patch (control group) for the 12-week duration.
Learn more